Human OPG ELISA Kit
KOA0285
1 Kit
ELISA
Human
93.7 pg/ml - 6000 pg/ml
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Human OPG AccuSignal ELISA Kit - KOA0285
MGC29565, MGC93568, OCIF, OPG, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TNFRSF 11B, TNFRSF11B, TR 1, TR1, TR11B_HUMAN, Tumor necrosis factor receptor superfamily member 11B
ELISA Kit
93.7 pg/ml - 6000 pg/ml
Target Details
TNFRSF11B - View All TNFRSF11B Products
Human
Expression system for standard: NSO; Immunogen sequence: E22-L401
Natural and recombinant human OPG. There is no detectable cross-reactivity with other relevant proteins.
O00300 - UniProtKB
NP_002537.3 - NCBI Protein
Application Details
ELISA
Useful in Sandwich ELISA for Quantitative Detection of Antigen. Aliquot 0.1ml per well of the 6000pg/ml, 3000pg/ml, 1500pg/ml, 750pg/ml, 419pg/ml, 187.5pg/ml, 93.7pg/m human OPG standard solutions into the precoated 96-well plate. Add 0.1ml of the sample diluent buffer into the control well (Zero well). Add 0.1ml of each properly diluted sample of human cell culture supernates, serum, plasma(heparin, EDTA), saliva or urine to each empty well. It is recommended that each human OPG standard solution and each sample be measured in duplicate.
Formulation
Heparin Sodium
Shipping & Handling
Wet Ice
Store vials at 4°C prior to opening. Centrifuge product if not completely clear after standing at room temperature. This product is stable for 6 months at 4°C as an undiluted liquid. Dilute only prior to immediate use. For extended storage freeze at -20°C or below for 12 months. Avoid cycles of freezing and thawing.
See kit insert for complete instructions.
Osteoprotegerin(OPG) is identical to osteoclastogenesis inhibitory factor(OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation. Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system. The standard product used in this kit is recombinant OPG, a 55KDa glycoprotein.
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.